We are proud to partner with Cincinnati Children's advancing groundbreaking medical research. 🌟 KME-0584, a small-molecule drug developed under the leadership of Dr. Daniel Starczynowski, represents a major milestone in drug discovery at Cincinnati Children's. It offers hope to patients battling relapsed/refractory AML and high-risk MDS. From concept to IND filing, this achievement showcases the power of collaboration. A special nod to Kurome Therapeutics, Inc., National Center for Advancing Translational Sciences (NCATS), and the brilliant researchers who made this possible. Together, we’re transforming innovation into lifesaving treatments. Read more about this incredible journey in the Research Horizons Science Blog below ⬇️ #DrugDevelopment #Innovation #BiotechStartup #CancerResearch #CincinnatiChildrens #AML #MDS
Cincinnati Children's is establishing a blueprint of how drug discovery can be done at an academic medical center. Developed from research led by Daniel Starczynowski, PhD, the KME-0584, a small molecule drug aims to treat refractory/relapsed AML and high-risk MDS, both of which have limited treatment options. This is one of the few therapeutics developed at Cincinnati Children's from initial concept through the now open IND filing. Special thanks to our collaborators at Kurome Therapeutics, Inc., CincyTech, National Center for Advancing Translational Sciences (NCATS), and the dedicated researchers at Cincinnati Children's who made this possible. Together, we're bringing hope to thousands of patients with limited cancer treatment options. Read more in our Research Horizons Science Blog article. #DrugDevelopment #Innovation #BiotechStartup #CancerResearch #TechnologyTransfer #CincinnatiChildrens #AML #MDS